SciELO - Scientific Electronic Library Online

 
vol.35 issue1Elementos de predicción en la nefropatía por inmunoglobulina AValor de la ortopantomografía en la poliposis familiar de colon author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Cubana de Medicina

On-line version ISSN 1561-302X

Abstract

SANTANA PEREZ, Felipe  and  ANDINO VALDES, Nieves. Tratamiento de hiperprolactinemia idiopática con lisurida. Rev cubana med [online]. 1996, vol.35, n.1, pp. 17-23. ISSN 1561-302X.

Lysuride, 8-amino-argolene has a very important agonist activity for dopamine, and hence for prolactin secretion. A clinical trial was carried out in 20 women presenting with non-tumor hyperprolactinemia with the aim of assessing the efficacy and safety of this drug as a therapeutic agent for the treatment of idiopathic hyperprolactinemia in comparison to bromocriptine. Patients were randomly assigned to 2 groups of treatment; Group I received bromocriptine (Parlodel ) in a dose of 2.5 mg/day and Group II received lysuride (Lysemil forte) in a dose of 0.2 mg/day. Plasma prolactin levels (PRL) were determined as follows: Basal PRL and on days 1, 7, 14, 21, and 28 after treatment. No significant statistical differences were found between both drugs regarding plasma prolactin levels. Eight patients from group I and 11 from group II presented with side-effects. Constipation was reported as the most frequent side-effect. It is concluded that lysuride is as effective as bromocriptine for reducing prolactin levels in patients with idiopathic hyperprolactinemia, and that its side-effects are similar to the ones of bromocriptine, but lysuride appears to be cheaper from the economic point of view. That's why we recommend to evaluate its short-term efficacy in order to use it as an alternative effective, safe, and economic treatment modality.

Keywords : HYPERPROLACTINEMIA [drug therapy]; LYSURIDE [therapeutic use]; BROMOCRIPTINE [therapeutic use]; PROLACTIN [blood]; AMENORRHEA, GALACTORRHEA; OLIGOMENORRHEA.

        · abstract in Spanish     · text in Spanish

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License